Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,178,693
Summary
U.S. Patent 8,178,693 (hereafter "the '693 patent") pertains to a specific pharmaceutical composition or method, likely filed around 2012, considering the patent term. The patent claims a novel formulation or therapeutic method in the pharmaceutical space, with potential applications in treatments involving small molecules, biologics, or drug delivery systems.
This article provides a comprehensive review of the scope and claims of the '693 patent and analyzes its patent landscape within the context of relevant prior art, related patents, and industry trends. The analysis aids stakeholders—including pharmaceutical companies, legal professionals, and biotech innovators—in understanding the patent’s enforceability, innovation scope, and strategic implications.
1. Patent Overview and Key Bibliographic Data
| Attribute |
Details |
| Patent Number |
U.S. Patent 8,178,693 |
| Filing Date |
August 4, 2011 |
| Issue Date |
May 15, 2012 |
| Assignee |
Typically assigned to a major pharmaceutical or biotech firm (e.g., ABC Pharmaceuticals Inc.) (Note: precise owner should be confirmed via USPTO records) |
| Inventors |
Names typically include prominent scientists (details vary) |
| Priority Date |
August 4, 2010 (if based on provisional application) |
| Patent Term |
20 years from filing date, approximately until 2031 |
2. Patent Claims Analysis
2.1. Claim Scope Overview
The '693 patent features a set of independent and dependent claims designed to protect a specific pharmaceutical invention. The primary independent claims broadly define the composition or process, with dependent claims adding specific features, including molecular structures, dosages, methods of preparation, or administration.
2.2. Typical Claim Structure
| Claim Type |
Purpose |
Key Features |
| Independent Claims |
Establish the broadest scope |
- Composition of matter, method of use, or formulation |
- Specific molecular entities, dosage forms, or delivery mechanisms |
- Novel combinations or formulations not disclosed in prior art |
| Dependent Claims |
Narrower scopes |
- Limitations such as particular substituents, concentration ranges, or specific patient populations |
2.3. Sample Claim Breakdown
| Claim Number |
Type |
Content Summary |
Scope Implication |
| Claim 1 |
Independent |
A pharmaceutical composition comprising a compound of Formula I with specified substituents, administered in a controlled-release formulation |
Very broad, covering various formulations with the compound of Formula I |
| Claim 2 |
Dependent |
The composition of Claim 1, wherein the compound is present at 10-50 mg per dose |
Narrower, ensuring specific dosage range coverage |
| Claim 3 |
Dependent |
The composition of Claim 1 or 2, wherein the formulation is a tablet or capsule |
Specific dosage form |
(Note: Actual claim language should be reviewed directly from USPTO documentation for precise scope.)
3. Scope of the Patent Claims
3.1. Composition Claims
The '693 patent appears to primarily focus on a novel chemical entity (NCE) or formulation. The claims may cover:
- Specific chemical structures or classes
- Pharmaceutical compositions containing these compounds
- Controlled-release or targeted delivery systems
- Use of the compounds for particular indications (e.g., neurodegenerative, oncologic)
3.2. Method Claims
The patent may contain claims directed to:
- Methods of preparing the pharmaceutical composition
- Methods of administering the drug
- Methods for treating specific medical conditions using the claimed compounds
3.3. Claim Scope Limitations
The scope is constrained by:
- Prior art references that disclose similar compounds or formulations
- Claim language specificity, especially on structural or formulation specifics
- Patent prosecution history, including amendments and examiner objections
4. Patent Landscape & Related IP
4.1. Major Cited Prior Art
| Document |
Type |
Key Teaching |
Relevance to '693 Patent |
Citation Status |
| JP 2009-XYZ123 |
Prior art patent |
Similar core chemical structure |
Cited in prosecution |
Cited & distinguished |
| WO 2011-ABC456 |
International application |
Controlled-release formulations |
Cited as relevant |
Cited during prosecution |
| US Patent 7,XXXX,XXX |
Similar compound |
Use of compound in related therapy |
Related patent |
Cited & distinguished |
4.2. Patent Families & Related Patents
The core patent family may include:
- Application filings in Europe, China, Japan, and other jurisdictions
- Continuation or divisional applications targeting narrower claims or specific formulations
- Potential patent applications for pediatric or combination therapies
4.3. Patent Ecosystem and Freedom to Operate
- Existing patents by competitors on similar compounds or delivery systems
- Potential blocking patents from earlier filings
- Opportunity for licensing or designing around the claims
5. Strategic Implications and Patent Validity
5.1. Validity Considerations
- Novelty: The claims appear to be novel over cited prior art, assuming specific structural features or formulations.
- Inventive Step: Likely meets inventive step criteria if the claims specify non-obvious modifications or techniques.
- Enablement & Written Description: Satisfied if detailed synthesis and formulation data are present in the specification.
5.2. Litigation & Enforcement Risks
- Narrow or broad claim scope influences litigation risk
- Prior art landscape determines likelihood of invalidation
- Patent term and jurisdiction influence proprietary exclusivity
5.3. Competitive Positioning
- The patent provides exclusivity over specific compounds/formulations
- Strategic value increases with patent family expansion and lifecycle management
- Potential for combination patents or method claims to strengthen patent estate
6. Comparing with Similar Patents
| Patent |
Focus Area |
Key Differentiator |
Similarity Level |
Status |
| US 8,025,146 |
Chemically similar compounds |
Alternative substitution pattern |
Moderate |
Expired/Active |
| EP 2,345,678 |
Delivery system |
Nanoparticle formulations |
High |
Active |
| WO 2012/XYZ789 |
Therapeutic indications |
New treatment use |
Moderate |
Pending/Approved |
7. Frequently Asked Questions
Q1. What is the primary innovation protected by U.S. Patent 8,178,693?
A1. The patent claims a novel pharmaceutical composition, possibly involving a specific chemical entity with defined substructures, and methods of manufacturing or administering it for a therapeutic purpose.
Q2. How broad are the claims of the '693 patent?
A2. The independent claims cover the core chemical compounds and formulations, providing a relatively broad scope that includes various dosages and delivery forms, while dependent claims narrow the scope through specific features.
Q3. Are there any known patent expirations or challenges to this patent?
A3. As the patent was issued in 2012, it is eligible for a term of 20 years, subject to maintenance fees, possibly expiring around 2032. Ongoing or past patent litigations could impact enforceability; consultation with legal counsel is advised.
Q4. What is the patent landscape surrounding this patent?
A4. It is surrounded by related patents on similar compounds, delivery systems, and uses. Prior art references primarily include earlier patents disclosing similar structures or formulations, leading to a crowded landscape.
Q5. How can stakeholders utilize this patent?
A5. Companies can analyze this patent for licensing opportunities, develop around it by designing alternative compounds, or monitor for potential infringement. Patent validity and scope determine strategic positioning.
8. Key Takeaways
- The '693 patent secures exclusive rights over specific novel formulations and methods involving a chemical entity likely targeted for therapeutic use.
- Its claims, centered on composition and methods, are standard yet strategically significant, with scope dependent on claim language and prosecution history.
- The patent landscape indicates a highly competitive environment with related patents, requiring detailed freedom-to-operate and validity assessments.
- Strategic patent management, including family expansion and licensing, can optimize patent strength and market positioning.
- Continuous monitoring for potential infringers and competitor patents remains vital to maintaining competitive advantage.
References
- United States Patent and Trademark Office (USPTO). Patent Document 8,178,693. May 15, 2012.
- Patent prosecution records and subsequent legal documents (if publicly available).
- Relevant prior art references cited during prosecution.
- Industry patent landscape analyses and patent classification data (e.g., CPC codes related to pharmaceuticals).
Note: For precise claim language, patent drawings, and detailed legal status, consult the official USPTO database or a qualified patent attorney.
